Methicillin-resistant Staphylococcus aureus (MRSA) is a major multidrug-resistant bacterial pathogen. The evolution of MRSA is dynamic posing an ongoing threat to humans. The evolution of MRSA includes horizontal gene transfer, which is mediated by mobile genetic elements, plasmids, and bacteriophages, and also mutations. In this review, we clarify the recent trends in MRSA from the perspectives of drug-resistance transfer and uncontrollable infections, particularly those occurring in community settings. We fi rst address the role of MRSA as a disseminator of multidrug resistance. We have studied the cell-to-cell transfer of drug resistance, in which transfer frequencies range from 10-3 to 10-8. The mechanisms of drug-resistance transfers include the self-transmission of large plasmids, the mobilization of small nonconjugative plasmids, the generalized transduction of phages, and the transfer of transposons with circular intermediates. We then discuss uncontrollable infections. Although several anti-MRSA agents have been developed, uncontrollable cases of MRSA infections are still reported. Examples include a case of uncontrollable sepsis arising from a community-associated MRSA (CA-MRSA) with the ST8/SCCmecIVl genotype, and a relapsing severe invasive infection of ST30/SCCmecIVc CA-MRSA in a student athlete. Some of these cases may be attributable to unique adhesins, superantigens, or cytolytic activities. The delayed diagnosis of highly adhesive and toxic infections in community settings may result in CA-MRSA diseases that are diffi cult to treat. Repeated relapse, persistent bacteremia, and infections of small-colony variants may occur. To treat MRSA infections in community settings, these unique features of MRSA must be considered to ensure that diagnostic delay is avoided.
Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) is a major multidrug-resistant (MDR) pathogen, recognized by the World Health Organization (WHO) in 2014 [1] . MRSA emerges from methicillin-susceptible S. aureus (MSSA) through the acquisition of the staphylococcal cassette chromosome mec (SCCmec) [2] [3] [4] . SCCmec is classifi ed into several types, each containing several subtypes [2]. The term "MRSA" includes healthcare-associated MRSA (HA-MRSA) and community-associated MRSA (CA-MRSA) [4, 5] . HA-MRSAs are most frequently associated with infections in hospital in-patients, and are opportunistic pathogens. They are usually resistant to those antibacterial drugs agents and well-characterized CA-MRSA clone is USA300 (ST8/ SCCmecIVa), which caused an epidemic of serious invasive infections in the United States in 2007 [4, 5, 13, 14] . USA300 has since progressed to a nosocomial MDR pathogen and a global pathogen [13, 15] . CA-MRSA often produces Panton-Valentine leukocidin (PVL) [4, 14, 16] , and ST8/SCCmecIVa (USA300) [4, 13] , ST30/SCCmecIV [3, 17] , ST59/SCCmecV [3, 18] , and ST80/SCCmecIV [3, 19] are representative PVLpositive lineages. SCCmecIV and SCCmecV are common among CA-MRSA [3, 4] . The expression of cytolytic peptides (for example, phenol-soluble medulins, PSMs) is elevated in CA-MRSAs [20] . The evolution of MRSAs is dynamic and they, therefore, pose an ongoing threat to humans. The evolution of MRSAs includes horizontal gene transfer, which is mediated by mobile genetic elements, plasmids, and bacteriophages (phages), and also mutations [3, 4, [21] [22] [23] [24] [25] [26] . In this review, we clarify the recent trends in MRSAs from the viewpoint of drugresistance transfer and uncontrollable infections, particularly, those occurring in community settings.
Methods
Our previously published data are used as the bases for this review. Data published by others are used to evaluate our data and to extend our discussion.
Results and Discussion
We describe MRSAs as disseminators of multidrug resistance. We have studied the cell-to-cell transfer of drug resistance in MRSAs isolated in Russia, Japan, and Taiwan using a mixed culture method on membrane fi lters (fi lter mating). These previous data are summarized in Table 1 [18, 23, 24, [27] [28] [29] [30] . A large plasmid of ca. 40 kb (pWMUP1), carrying the mupirocin-resistance gene (mupA), and a small 2.9-kb plasmid (p16K-1), carrying the chloramphenicol-resistance gene (cat), are transferred at high transfer frequencies of 10 -3 (drug-resistance-acquiring recipients per donor). Other plasmids show moderate transfer frequencies (10 -4 to 10 -6 ) or low frequencies (10 -7 to 10 -8 ). No transfer frequencies are lower than 10 -9 for naturally occurring chromosomal gene mutations in gyrA and grlA, which generate levofl oxacin resistance, or in rpoB, which generate rifampicin resistance. The transfer of drug resistance is frequently observed in CA-MRSAs (ST8/SCCmecIV and ST59/SCCmecV), whereas it is rather rare in HA-MRSAs (ST239/SCCmecIII). However, an emerging variant clade of classical ST239/SCCmecIII/ spa3[t037], that was isolated from patients with urethritis in community settings in Vladivostok, Russia, and displays a divergent spa type (spa351[t030]) [23] , is more able to donate its drug resistance (for example, via the 2.9-kb cat plasmid p16K-1) than other HA-MRSAs. It is noteworthy that when transposon Tn554 (carrying the erythromycin-resistance gene ermA and spectinomycinresistance gene aad9/spc) is integrated into the bacterial chromosome, it can be transferred at low-to-moderate levels. Since Tn554 forms a circular intermediate DNA in an MRSA cell [23, 31, 32] , there is a possibility that the Tn554 circular intermediate play a role in transfer, similar to small plasmids. Transposon Tn4001 (carrying the gentamicin-resistance gene aacA-aphD) in ST239/SCCmecIII/spa351[t030] can also be transferred at moderate levels. This Tn4001 occurs as a part of a larger transposon-like, mobile-element structure, MES16K [23] , which may provide genetic background for effi cient transfer. In the MRSA lineage ST8/SCCmecIVl, Tn4001 is simply integrated into the bacterial chromosome [28] and shows no transfer. Another large 32-kb plasmid (pWSI1) that is transferred at low-to-moderate frequencies carries the qac gene, encoding for resistance to antiseptics (quaternary ammonium; benzalkonium/benzethonium chloride, acrofl avin, and ethidium bromide), and also the edin/ednA gene, which encodes the virulence factor, epidermal cell differentiation inhibitor (EDIN) [27] [28] [29] [30] . Two modes of transfer are observed: one only occurs on a fi lter (for example, a ca. 40-kb plasmid [pWMUP1] containing mupA) and the other occurs on agar plates, both with and without fi lter (for example, a 32-kb plasmid [pWSI] containing qac and edin and a 2.9-kb plasmid [p16K-1] containing cat). Staphylococcal plasmid transfer requires cell-to-cell contact and is, therefore, generally performed on agar plates with membrane fi lters [33] [34] [35] . Large plasmids of 40-60 kb (a well-characterized example is the pSK41/pGO1 family) can be transferred to other bacterial cells by conjugation, with transfer frequencies ranging from 10 -4 to 10 -7 [33] [34] [35] . The conjugative transfer genes (tra) have been reported. For example, the 52-kb self-transmissible plasmid pGO1 has a 13.8-kb trs gene and 14 open reading frames (ORFs, A to N) [35] ; its phenotype is resistance to gentamicin, trimethoprim, and quaternary ammonium. A ca. 40-kb mupA plasmid [pWMUP1] may have one of the highest transfer frequencies of all the conjugative plasmids. The transfer region (tra) of pWMUP1 is under investigation. Two other large plasmids, 26-kb pPM1 containing blaZ, tetK, and cadD and 32-kb pWSI1 containing qac and edin, show no homology to the trs region of pGO1. Large conjugative plasmids can mobilize the transfer of some small plasmids (3.5-14.5 kb) into other bacterial cells [36] [37] [38] , as shown in Fig. 1 . These small plasmids are called nonconjugative mobilizable plasmids. The process of mobilization [36, 37] is as follows: 1) fi lter mating provides close contact between the donor and recipient cells; 2) the tra region on a large conjugative plasmid creates a mating pore (the "small needle") between the donor and recipient (the "small needle" formed by the type IV secretion system allows DNA to be injected into the recipient); 3) relaxase (Mob), encoded by the mob gene, interacts with the 5' plasmid sequence at the origin of transfer (oriT) to form (often with accessory proteins) a complex called "relaxasome"; 4) the relaxasome is recruited to the mating pore to transfer the plasmid DNA into the recipient cells; and 5) plasmid replication during conjugation, in both the donor and recipient, occurs via a rolling circle mechanism. Thus, the transfer of small nonconjugative mobilizable plasmids requires the help of large conjugative plasmids. Examples of Mob and ori, that differ from that shown in Fig. 1 have also been reported [36, 37] . Rolling-circle-replicating plasmids are generally less than 5 kb in size and are cryptic or encode only a single resistance gene [38] . The erythromycin-resistance gene ermC is located on nonconjugative mobilizable plasmids and is the erm gene most widespread among the staphylococci [39] . Tetracyclineresistance gene tetK is located on 4.4-4.7-kb nonconjugative mobilizable plasmids, with transfer frequencies (10 -9 ) [40] . The chloramphenicol-resistance gene cat is also located on small (e.g., 2.9-kb) plasmids in many cases [23, 24] , although cat is located on the unique movable element structure MES PM1 on the chromosome of MRSA (ST59/SCCmecV) in Taiwan [18] and cat-positive cases are very rare in Japan [24] . The distribution of plasmids in Krasnoyarsk, Russia is unique [23, 24] . Many MRSAs only carry a 2.9-kb cat plasmid (e.g., pOC3 and pOC8), but often carry two species of cat plasmid. In Russia, inexpensive chloramphenicol is commonly administered to patients without a doctor's prescription as an ointment for skin injuries or burns as a tablet for gastroenteritis or as an eye lotion, exerting a strong selective pressure on MRSAs to carry a cap plasmid [23, 24] . This suggests that small plasmids contribute to the micro-evolution of MRSA, adapting to community settings of each region in the world. Plasmids are also transferred by phages [37, 41] . In MRSAs, phage DNA can be integrated into the MRSA genome as a prophage. Prophages enter the lytic cycle if they are induced spontaneously or by the administration of, for example, fl uoroquinolone. During the lytic cycle, the MRSA DNA (less than 45 kb), including plasmids, is packed into the phage particles with the phage genome (45 kb in size) to produce the phage capsid. The transducing particles then infect other bacterial cells and transfer the DNA contained within them. Thus, the phage transduction (generalized transduction) can also contribute to the transfer of small nonconjugative plasmids. The reports of S. aureus pathogenicity islands (SaPIs) are interesting in terms of phages. SaPIs are located in the MRSA genome and carry various combinations of superantigen genes [37] . SaPIs require a helper phage for their transfer [37] . They also play a role in generalized transduction through SaPI capsids, in a process called "island-mediated transduction" [37] . MRSAs have a restriction-modifi cation system (type I or typeIII-like) to block horizontal gene transfer [42, 43] . Therefore, some MRSAs will block the invasion of plasmid or phage DNA. The data in Table 1 show that a high-level transfer group of a ca. 40-kb plasmid (pWMUP1) containing mupA may be a new type of conjugative plasmid. The high transfer ability of a 2.9-kb cat-containing plasmid (p16K-1) in a unique genetic background, ST239/SCCmecIII/spa351[t030], requires further study. The cell-to-cell transmission of Tn554 (ermA/ aad9), through a circular intermediate, is a new fi nding. Some small plasmids (<5 kb in size) must be mobilized by the machinery of helper conjugative plasmids. In our studies, we have detected no vanA-gene-carrying plasmid, that is associated with vancomycin-resistant Staphylococcus aureus (VRSA) [44] . We next discuss uncontrollable infections. Although several anti-MRSA agents have been developed, uncontrollable cases of MRSA infections are still reported. Examples include an uncontrollable sepsis (with pulmonary embolism and multiple organ failure) attributed to CA-MRSA ST8/ SCCmecIVl [29] , and a relapsing invasive infection of CA-MRSA ST30/SCCmecIVc in a student athlete [45, 46] . Superantigens [47] provide the toxicity of CA-MRSA infections. From the perspective of MRSA genetics, it is noteworthy that the classical HA-MRSA ST5/SCCmecII lineage [48] , which is still predominant in Japan, and the emerging CA-MRSA ST8/ SCCmecIVl (CA-MRSA/J), which is associated with severe invasive diseases in Japan, including a fatal case [28, 29] , share similar features, including the superantigen gene cluster (tst, sec, sell), suggesting that these confer selective advantages. In Krasnoyarsk, Russia, a unique derivative of ST239/SCCmecIII/spa3[t037], which has acquired the tst gene, is widespread [24] . The tst gene product, toxic syndrome toxin 1 (TSST-1), is associated with toxic shock syndrome (TSS) [47] , in which a "cytokine storm" is generated [47] , and with invasive endocarditis [47] . Among the staphylococcal exotoxins (SEs) that act as superantigens, TSST-1 is the most potent because it polyclonally activates T cells (and also macrophages) at picomolar concentrations [47, 49] . TSST-1 also acts as an immune evasion factor [47, 50] . The delayed diagnosis of this possible toxic feature of superantigens, which may occur in community settings, may make CA-MRSA diseases diffi cult to treat. This may also be the case for the superantigen staphylococcal enterotoxin B (SEB), because SEB induces danger signals in host cells, resulting in multiorgan injury and toxic shock [49] . The SEB gene is associated with MRSAs with community-associated features; for example, SEB-producing CA-MRSAs include ST59/SCCmecV in Taiwan [18] and emerging ST764 variant of HA-MRSA ST5/SCCmecII, which has the virulence determinants of CA-MRSA, in Japan [51] . Adhesins play a key role in CA-MRSA infections in community settings, in bacterial spread and as virulence factors. For example, a key feature of CA-MRSA/J is the spj gene on SCCmecIV. spj encodes a large and highly variable cell-wallanchored protein (Spj) [30] . CA-MRSA/J (ST8/SCCmecIVl) is classifi ed into different pathotypes based on the unique spj gene [29, 30] : i) a strongly invasive type, isolated from a fatal infection [29] , which was highly invasive in a HEp-2 cell infection model [29, 30] , and has a short spj gene (lacking the sequence encoding 11/22-amino acid repeats) [30] ; and ii) a possible adherent type, isolated from bullous impetigo [27] , which was adherent in a HEp-2 cell infection model [29, 30] , and has a large spj gene (containing the long sequence encoding 11/22-amino acid repeats) [30] . A delay diagnosis of the strongly invasive type may results in dangerous infections. Like USA300, CA-MRSA/J spreads widely in community settings, but the situations differ. PVL-negative CA-MRSA/J causes bullous impetigo in many cases and spreads directly or indirectly through skin contact [27, 30] . In contrast, PVLpositive USA300 causes severe skin lesions such as furuncles and carbuncles with large abscesses, initially called "spider bite" [52] . These abscesses allow USA300 to spread widely through skin contact either directly or indirectly [4, 53] . It is noteworthy that PVL-negative CA-MRSA/J causes severe invasive infections, attributable to a set of virulence factors (for example, Spj, TSST-1, and PSMα) [29, 30] that differ from those of USA300 [4] . PVL-positive CA-MRSA ST30/SCCmecIV is also a unique and dangerous cause of severe invasive infections. It caused the fi rst reported death case in Japan, in a child with pneumonia [54] . It was also associated with a relapsing invasive infections in a student athlete [45, 46] : the fi rst episode involved osteomyelitis and simultaneous iliopsoas and piriformis abcesses, adjacent to the sacroiliac joint; the second and third episodes involved abscesses in tissues adjacent to the sacroiliac joint four and eight months after the fi rst treatment. ST30/SCCmecIV is a globally spread CA-MRSA [3, 17, 55] , and is characterized by a unique combination of the adhesion genes cna and bbp [17, 27, 54, 56] , similar to globally spread S. aureus ST121 (or its MRSA) [57] . The ST30 lineage has unique PSMα cytolytic activities [14, 20, 58] and causes blood stream infections with complications such as seeding to organs [58] . Small-colony variants (SCVs) are also associated with refractory infections [59] , although usually in healthcare settings. SCVs have damaged bacterial cell structures [60, 61] , and are resistant to drugs such as aminoglycosides, sulfamethoxazole, trimethoprim, fl uoroquinolones, fusidic acid, and triclosan [62] . The case shown in Fig. 2 is a daptomycin-resistant SCV that emerged from HA-MRSA ST239/SCCmecIII during the treatment of a patient with daptomycin for septic anthritis [61] . SCVs of S. aureus have been isolated from a variety of infections including persistent and relapsing infections. Well-characterized SCVs include hemin-dependent SCVs, menadione-dependent SCVs, and thymidine-dependent SCVs [59] . MRSA bacteremia, which persist despite antibiotic therapy is a signifi cant cause of morbidity and mortality [63] . Persistent MRSA bacteremia is defi ned as a positive blood culture maintained for 3 -7 days after treatment [63] . Bacteremia of increased duration is associated with metastatic and complex infections [63] . A better understanding the pathogen-host interactions in persistent MRSA infections in vivo is required [63] . Therefore, to treat MRSA infections in community settings, the unique features of MRSAs (or S. aureus) described above must be considered to ensure that delayed diagnoses are avoided. The fi gure is drawn based on the information in references [36] [37] [38] . Abbreviation: Chr, chromosome (MRSA DNA); ss, single-stranded (DNA); ds, double-stranded (DNA). Yellow, peptidoglycan (cell wall); purple, mating pore (type IV secretion system); blue, large conjugative plasmid DNA; red, small plasmid DNA: green, relaxase protein. Relaxase binds to the 5' end (at oriT) of the plasmid ss DNA, which forms during the rolling-circle replication of the plasmid DNA, generating a nucleoprotein complex, referred to as a "relaxasome". The relaxasome recruits the 5' end of the plasmid ss DNA to the mating pore. The type IV secretion system then transfers the 5' end of the plasmid ss DNA to the recipient cell through its "needle". The transferred plasmid ss DNA is converted to ds DNA in the recipient cell. In this fi gure, the small plasmid has an oriT mimic (oriT'), therefore, relaxase also binds to the 5' end of the small plasmid's ss DNA, and recruits it to the mating pore for mobilization. For this conjugation process in S. aureus (MRSA), the donor and recipient cells must be in close contact because S. aureus (MRSA) has a thick peptidoglycan payler.
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